SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ENTA

Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$7.62-$0.36 (-4.51%)
 
Market cap
$222M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 21, 2013
Website
Market Cap$222.19M-44.2%
Revenue (ttm)$63.00M-3.6%
Net Income-$68.25M+16.7%
EPS-$2.35+38.8%
Shares Out29.16M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume457,635
Open$7.82
Previous Close$7.98
Day's Range$7.56 - $7.99
52-Week Range$7.56 - $17.15
Beta0.96
AnalystsBuy
Price Target$20.00(+162.47%)
Earnings DateFeb 8, 2027

About ENTA

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

Address
4 Kingsbury Avenue, Watertown, MA, 02472, US
Market Cap
222 million
Employees
74
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$183.17K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $20.00 (+162.5%)

1 firm rating ENTA in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From ENTA’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-4.51%
5 Days
-30.73%
1 Month
-34.42%
6 Months
-45.38%
1 Year
-44.18%

$ENTA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ENTA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ENTA's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ENTA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ENTA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ENTA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ENTA

VTIVanguard Morningstar Total Stock Market ETF$7.40M
IWMiShares Russell 2000 ETF$5.77M
VXFVanguard Extended Market ETF$3.14M
VTWOVanguard Russell 2000 ETF$1.78M
SLYSPDR S&P 600 Small Cap ETF$1.77M
IBBiShares Biotechnology ETF$1.63M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ENTA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
35

News check: Q4 earnings miss on revenue with net loss, though loss narrowed; mixed underlying fundamentals weigh on sentiment.

Recent Insider Activity

Buys
0
Sells
9
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

GERMETFMG Treatments, Testing and Advancements ETF0.62%
QQQSInvesco NASDAQ Future Gen 200 ETF0.49%
SBIOALPS Medical Breakthroughs ETF0.21%
SLYSPDR S&P 600 Small Cap ETF0.10%
DMRSDeltaShares S&P 600 Managed Risk ETF0.09%
IWCiShares Micro-Cap ETF0.08%
FSEVFidelity Enhanced Small Cap Value ETF0.06%
STSBiShares Factors US Small Blend Style ETF0.05%
FEACFidelity Covington Trust - Fidelity Enhanced U.S. All-Cap Equity ETF0.05%
FSEGFidelity Enhanced Small Cap Growth ETF0.05%
IBBiShares Biotechnology ETF0.02%
IBBQInvesco Nasdaq Biotechnology ETF0.02%

Weight is the stock’s share of each fund’s holdings.